Fig. 1

LncRNA-IUR1 is identified as a novel lncRNA that is induced by imatinib treatment in Bcr-Abl-positive leukemic cells. A, B Hierarchical clustering analysis of lncRNAs differentially expressed in K562 cells treated with or without imatinib. The values from three independent experiments were displayed (A). RT-PCR analysis of expression of selected lncRNAs in K562 cells treated with imatinib (B). C, D RT-PCR (C) and quantitative real-time PCR (D) were performed to detect the expression of lncRNA-IUR1 in K562 cells treated with imatinib. Data (D) are presented as mean ± SEM. n = 3, **p < 0.01, ***p < 0.001. E, F RT-PCR analysis of Bcr-Abl expression in the primary peripheral blood lymphocytes from Bcr-Abl-positive CML patients and normal subjects (E). Quantitative real-time PCR was performed to examine the expression of lncRNA-IUR1 in primary leukemic cells from Bcr-Abl-positive CML patients and normal control (F). n = 4, means ± SEM, **p < 0.01. G The CPC scores for human lncRNA-IUR1 transcripts and the control gene GAPDH (http://cpc2.cbi.pku.edu.cn/). The CPC score of each lncRNA-IUR1 transcript was minus, indicating “noncoding”. H RT-PCR was performed to examine cytoplasmic or nuclear lncRNA-IUR1 RNA levels in K562 cells. GAPDH was served as the cytoplasmic control, and U6 was the nuclear control